Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of “Moderate Buy” from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been given an average recommendation of “Moderate Buy” by the seventeen ratings firms that are currently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $216.19.

A number of research firms have recently weighed in on ALNY. BMO Capital Markets reaffirmed an “outperform” rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. HC Wainwright upped their price target on Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Needham & Company LLC reiterated a “buy” rating and set a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 2nd. Chardan Capital restated a “buy” rating and set a $225.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC grew its position in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Altitude Crest Partners Inc. acquired a new stake in Alnylam Pharmaceuticals in the first quarter valued at approximately $30,000. Quent Capital LLC grew its holdings in Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 123 shares during the last quarter. Anchor Investment Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $38,000. Finally, Robeco Institutional Asset Management B.V. increased its position in shares of Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $153.86 on Wednesday. The business’s fifty day moving average is $150.01 and its 200 day moving average is $162.56. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $218.88. The company has a market capitalization of $19.46 billion, a PE ratio of -57.41 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. Alnylam Pharmaceuticals’s revenue was up 54.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.40) EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals will post -3.77 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.